Sakagami Kazunari, Yasuhara Akito, Chaki Shigeyuki, Yoshikawa Ryoko, Kawakita Yasunori, Saito Akio, Taguchi Takeo, Nakazato Atsuro
Medicinal Chemistry Laboratories, Taisho Pharmaceutical Co., Ltd, Saitama-shi, Saitama 331-9530, Japan.
Bioorg Med Chem. 2008 Apr 15;16(8):4359-66. doi: 10.1016/j.bmc.2008.02.066. Epub 2008 Feb 26.
In this paper, we describe the synthesis of (+)-(1R( *),2R( *))-2-[(1S( *))-1-amino-1-carboxy-2-(9H-xanthen-9-yl)-ethyl]-1-fluorocyclopropanecarboxylic acid (+)-16a, a compound, that is, fluorinated at the alpha position of the carboxylic acid in the cyclopropane ring of a group II mGluRs antagonist, 1 (LY341495), using a previously reported stereoselective cyclopropanation reaction. The fluorinated compound (+)-16a exhibited almost the same affinity (IC(50)=3.49 nM) for mGluR2 as 1 but had a superior pharmacokinetic profile. Furthermore, a marked elevation of the plasma levels of (+)-16a was observed following the administration of a prodrug, (+)-17.
在本文中,我们描述了(+)-(1R(),2R())-2-[(1S(*))-1-氨基-1-羧基-2-(9H-占吨-9-基)乙基]-1-氟环丙烷羧酸(+)-16a的合成,该化合物是通过先前报道的立体选择性环丙烷化反应,在II组代谢型谷氨酸受体拮抗剂1(LY341495)的环丙烷环中羧酸的α位进行氟化得到的。氟化化合物(+)-16a对代谢型谷氨酸受体2的亲和力(IC(50)=3.49 nM)与1几乎相同,但具有更优的药代动力学特征。此外,在前药(+)-17给药后,观察到(+)-16a的血浆水平显著升高。